Inclusion Criteria:
- Stage III (unresectable) or Stage IV melanoma from a cutaneous or an unknown primary.
- Histologic proof of melanoma reviewed and confirmed at MSKCC
- Measurable disease (RECIST criteria)
- No prior chemotherapy for melanoma. Prior interferon, interleukin-2 or vaccine
therapy are allowed.
- No other concurrent chemotherapy, immunotherapy, or radiotherapy
- Karnofsky performance status ≥ 60
- Adequate organ function defined as follows: ANC > 1500, Platelets > 100,000,
creatinine < 2, Alkaline Phosphatase, AST and total bilirubin < 1.5x upper limit of
normal. For patients with suspected Gilbert's syndrome bilirubin will not be a
requirement.
- Tumor tissue for MGMT promoter methylation analysis and/or IHC must be available. In
most cases, this will be unstained slides from previously-obtained paraffin-embedded
tumor material. If this is not available, patients must have an easily-accessable
tumor for biopsy (e.g. skin or lymph node).
Exclusion Criteria:
- History of CNS metastases unless brain metastases have been resected and the patient
has been free from CNS recurrence for 6 months.
- Uveal or mucosal melanoma primary
- Frequent vomiting or medical conditions that could interfere with oral medication
intake
- Serious infection requiring antibiotics, or nonmalignant medical illnesses that are
uncontrolled or whose control might be jeopardized by the complications of this
therapy.
- History of HIV infection even if on HAART
- Immunosuppressive drugs
- High dose vitamins and herbs
- Other on-going investigational therapy, concurrent chemotherapy, immunotherapy or
radiotherapy.